Share this article
Share this article
ResearchAndMarkets.com s offering.
This report provides comprehensive insight on clinical and non clinical factors that are driving the peptide drug conjugate market and its impact on the global pharmaceutical market landscape. The report has been prepared in a view to deeply profile the current market trends along with the commercial opportunity and clinical insight on only approved peptide drug conjugate Pepaxto. Report also includes insight on more than 20 approved peptide drug conjugates in clinical pipeline.
Global Peptide Drug Conjugate Market & Clinical Trials Insight 2026 Report Highlights:
First FDA Approved Peptide Drug Conjugate: Pepaxto (Melphalan Flufenamide)
Peptide Drug Conjugate Market Size Clinical Trials Future 2026 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Global Peptide Drug Conjugate Market Opportunity Clinical Trials Insight 2026
USA - English
News provided by
Share this article
Global Peptide Drug Conjugate Market and Clinical Trials Insight 2026 Report Highlights:
First FDA Approved Peptide Drug Conjugate: Pepaxto (Melphalan Flufenamide)
Pepaxto Clinical and Commercial Insight: Dosage, Patent, Price, Sales Forecast
Peptide Drug Conjugate Sales Opportunity: US, Europe, Japan and South Korea
Global Peptide Drug Conjugate Clinical Pipeline: > 20 Drugs
Clinical Trials Insight by Company, Country, Indication
Patent Insight of Peptide Drug Conjugates
Profile and Clinical Pipeline Insight of Companies Developing Peptide Drug Conjugates Global Peptide Drug Conjugate Market and Clinical Trials Insight 2026 provides comprehensive insight on clinical and non clinical factors that are driving the peptide drug conjugate market and its impact on the global pharmaceutical market landscape. The report has been prepared in a vi
Share this article
Share this article
MONCTON, NB, Dec. 17, 2020 /CNW/ - Soricimed Biopharma Inc., ( Soricimed ), a privately-held, science-based, clinical stage company focused on the development and commercialization of first-in-class targeted cancer therapeutics, today announced that it will investigate the potential therapeutic role its cancer drug candidate, SOR-C13, can play in helping relieve or prevent severe immune response to the SARS CoV-2 virus.
Soricimed is currently developing SOR-C13, a TRPV6 calcium channel inhibitor, for the treatment of solid-tumour cancers. SOR-C13 is designed to decrease calcium concentrations inside cancer cells to inhibit calcium-dependent cancer cell proliferation and induce the death of tumour cells overexpressing TRPV6.